HRP20191711T1 - Oftalmološki pripravak - Google Patents
Oftalmološki pripravak Download PDFInfo
- Publication number
- HRP20191711T1 HRP20191711T1 HRP20191711T HRP20191711T1 HR P20191711 T1 HRP20191711 T1 HR P20191711T1 HR P20191711 T HRP20191711 T HR P20191711T HR P20191711 T1 HRP20191711 T1 HR P20191711T1
- Authority
- HR
- Croatia
- Prior art keywords
- ophthalmic preparation
- preparation according
- ophthalmic
- eye
- fatty acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 6
- 239000002904 solvent Substances 0.000 claims 8
- -1 sorbitan fatty acid ester Chemical class 0.000 claims 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940100242 glycol stearate Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Oftalmološki pripravak koji sadrži disperziju poliafrona,
pri čemu disperzija poliafrona sadrži barem jedan neionski, nehalogenirani surfaktant.
2. Oftalmološki pripravak u skladu s patentnim zahtjevom 1 u obliku tekućine, i/ili u obliku kapi za oči.
3. Oftalmološki pripravak u skladu s patentnim zahtjevima 1 ili 2 koji sadrži farmaceutski aktivnu tvar, poželjno pri čemu je farmaceutski aktivna tvar odabrana iz grupe koja se sastoji od antihistaminika, beta blokatora, kortikosteroida, prostaglandina, nesteroidnih protuupalnih lijekova (NSAR), imunološkog modulatora, anestetika, antibiotika, inhibitora ugljične anhidraze, vazokonstriktora, i smjesa dviju ili više navedenih tvari.
4. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu farmaceutski aktivna tvar sadrži ciklosporin.
5. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu pripravak ima osmolalnost od 200 do 600 mOsm/kg.
6. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, koji sadrži sredstvo za toničnost, poželjno odabran između šećera, šećernog alkohola, glikola, karbamida i smjesa dviju ili više navedenih tvari.
7. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva koji sadrži omega-3 masnu kiselinu.
8. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je pripravak pH vrijednosti od 3,5 do 9, poželjno od 5 do 8, a još poželjnije od 6 do 7,5.
9. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, koji sadrži sredstvo za geliranje i/ili viskoznosti je od 1 do 50 Pas pri brzini smicanja 1s-1.
10. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva koji sadrži farmaceutski prihvatljivo ulje odabrano iz skupine koja se sastoji od ricinusovog ulja, triglicerida dugog lanca, triglicerida srednjeg lanca, mineralnog ulja, silikona, fosfolipida, mono- i diglicerida i smjesa dviju ili više navedenih tvari; i/ili pri čemu je barem jedan neionski, nehalogenirani surfaktant odabran iz skupine koja se sastoji od polietilen glikol sorbitan estera masne kiselina, sorbitan estera masne kiseline, polietilen glikol estera masne kiseline, polietilen glikol stearat estera, polioksietilen glikol – blok – polipropilen glikol – blok – polioksietilen glikol – blok-a, polietilen glikol lauril estera i smjesa dviju ili više navedenih tvari.
11. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva u obliku gela za nanošenje na oko.
12. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je srednji promjer kapljica afrona od 0,5 do 50 µm.
13. Oftalmološki pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva za uporabu u liječenju ljudskog i/ili životinjskog oka topikalnom primjenom.
14. Oftalmološki pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 12 za uporabu u liječenju ljudskog i/ili životinjskog oka topikalnom primjenom, pri čemu je pripravak primijenjen izravno na površinu oka.
15. Postupak izrade oftalmološkog pripravka u skladu s bilo kojim od prethodnih patentnih zahtjeva koji uključuje sljedeće korake:
(i) dobivanje hidrofilnog otapala;
(ii) dobivanje hidrofobnog otapala;
(iii) miješanje hidrofilnog otapala s hidrofobnim otapalom u prikladnim uvjetima kako bi se dobio pripravak koji sadrži poliafronsku disperziju;
pri čemu hidrofilno otapalo i/ili hidrofobno otapalo sadrži surfaktant;
i pri čemu hidrofilno otapalo i/ili hidrofobno otapalo opcionalno sadrži farmaceutski aktivnu tvar.
16. Postupak u skladu s patentnim zahtjevom 15 koji se provodi u sterilnim i/ili aseptičkim uvjetima; i/ili koji nadalje sadrži autoklaviranje oftalmološkog pripravka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158099 | 2011-03-14 | ||
| EP12708358.2A EP2686017B1 (en) | 2011-03-14 | 2012-03-14 | An ophthalmic composition |
| PCT/EP2012/054498 WO2012123515A1 (en) | 2011-03-14 | 2012-03-14 | An ophthalmic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191711T1 true HRP20191711T1 (hr) | 2019-12-13 |
Family
ID=44483953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191711 HRP20191711T1 (hr) | 2011-03-14 | 2019-09-20 | Oftalmološki pripravak |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9610245B2 (hr) |
| EP (1) | EP2686017B1 (hr) |
| JP (1) | JP6105494B2 (hr) |
| CN (2) | CN108273065B (hr) |
| AU (1) | AU2012228273B2 (hr) |
| BR (1) | BR112013023458B1 (hr) |
| CA (1) | CA2829164C (hr) |
| DK (1) | DK2686017T3 (hr) |
| ES (1) | ES2736256T3 (hr) |
| HR (1) | HRP20191711T1 (hr) |
| HU (1) | HUE045467T2 (hr) |
| PL (1) | PL2686017T3 (hr) |
| PT (1) | PT2686017T (hr) |
| RU (1) | RU2639472C2 (hr) |
| SI (1) | SI2686017T1 (hr) |
| WO (1) | WO2012123515A1 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| PT2686017T (pt) | 2011-03-14 | 2019-10-24 | Drug Delivery Solutions Ltd | Uma composição oftálmica. |
| US11116769B2 (en) * | 2013-04-11 | 2021-09-14 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
| GB201410869D0 (en) * | 2014-06-18 | 2014-07-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| TWI756168B (zh) * | 2015-02-02 | 2022-03-01 | 日商參天製藥股份有限公司 | 多微泡及其眼瞼投予 |
| AU2016320905B2 (en) | 2015-09-11 | 2021-10-07 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
| US10286035B2 (en) | 2015-10-14 | 2019-05-14 | Paul Gavaris | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents |
| RS58292B1 (sr) * | 2016-07-07 | 2019-03-29 | Salvat Lab Sa | Oftalmološka kompozicija sa ricinusovim uljem i srednjim lancem triglicerida |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| CN108578617B (zh) * | 2018-04-09 | 2021-03-30 | 深圳市莱利赛生物科技有限公司 | 促进膝关节软骨再生用脐血间质干细胞药物的制备方法 |
| EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| CN112770812A (zh) | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| CN113166731A (zh) | 2018-10-05 | 2021-07-23 | 沃雅戈治疗公司 | 编码aav生产蛋白的工程化核酸构建体 |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| EP3911410A1 (en) | 2019-01-18 | 2021-11-24 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| EP3962536A1 (en) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| US20220364114A1 (en) | 2019-08-26 | 2022-11-17 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| TW202246516A (zh) | 2021-03-03 | 2022-12-01 | 美商航海家醫療公司 | 病毒蛋白之控制表現 |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024034592A1 (ja) * | 2022-08-09 | 2024-02-15 | 参天製薬株式会社 | Ｕｄｃａまたはその塩を含有する水性医薬組成物 |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS557228A (en) * | 1978-06-29 | 1980-01-19 | Lion Corp | Enzyme preparation |
| US4486333A (en) | 1981-04-10 | 1984-12-04 | Felix Sebba | Preparation of biliquid foam compositions |
| JPS59222409A (ja) | 1983-06-01 | 1984-12-14 | Nippon Redarii Kk | 消炎鎮痛ゲル軟膏剤 |
| CA1272953A (en) | 1984-10-08 | 1990-08-21 | Yuji Makino | Pharmaceutical composition for external use containing active-type vitamin d.sub.3 |
| JPH07553B2 (ja) | 1985-12-09 | 1995-01-11 | 佐藤製薬株式会社 | フイルム状製剤 |
| ZA888819B (en) | 1987-12-02 | 1990-07-25 | Ici Australia Operations | Process for preparing explosive |
| US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
| US4944938A (en) | 1988-12-16 | 1990-07-31 | Colgate-Palmolive Company | Antiperspirant and deodorant |
| US4999198A (en) | 1989-03-23 | 1991-03-12 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Polyaphrons as a drug delivery system |
| DE69130497T2 (de) | 1990-09-07 | 1999-04-22 | Wisconsin Alumni Res Found | Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis |
| US5840881A (en) | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| GB9300763D0 (en) | 1993-01-15 | 1993-03-03 | Leo Pharm Prod Ltd | Chemical compound |
| FR2710840B1 (fr) | 1993-10-04 | 1995-12-01 | Applic Transferts Technolo | Compositions viscoélastiques hautement concentrées en composés fluorés, leur préparation et leurs utilisations dans le domaine médical et en cosmétique. |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| FR2719220A1 (fr) | 1994-04-29 | 1995-11-03 | Lafon Labor | Nouvelle forme galénique pour l'administration transdermique. |
| US6538039B2 (en) | 1994-04-29 | 2003-03-25 | Laboratoire L. Lafon | Pharmaceutical dosage form for transdermal administration |
| US5474979A (en) * | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
| KR0159145B1 (ko) | 1995-02-24 | 1998-12-01 | 강박광 | 피부 약물 전달 체계용 에멀젼 네트웍의 제조방법 |
| US6238678B1 (en) | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
| US6165479A (en) | 1996-03-08 | 2000-12-26 | Disperse Technologies Limited | Dispersions comprising an oil-based biliquid foam and an aqueous gel |
| US5660858A (en) * | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
| KR100471341B1 (ko) | 1996-05-23 | 2005-07-21 | 제네시스 테크놀로지 가부시키가이샤 | 콘택트프로브및그것을구비한프로브장치 |
| NL1003503C2 (nl) | 1996-07-04 | 1998-01-07 | Negma Steba International Dev | Farmaceutische samenstelling voor orale toediening. |
| US5955097A (en) | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| ATE497384T1 (de) | 1997-12-10 | 2011-02-15 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
| US5990100A (en) | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
| EP1079813B1 (en) | 1998-04-29 | 2005-02-09 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| PT3146969T (pt) | 1999-04-23 | 2018-10-18 | Leo Pharma As | Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide |
| US6200581B1 (en) | 1999-04-28 | 2001-03-13 | Dow Corning Corporation | Elastomeric silicone terpolymer |
| DE19938668B4 (de) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| ATE275378T1 (de) | 2000-02-22 | 2004-09-15 | Color Access Inc | Wässrige kosmetische gele |
| US6576712B2 (en) | 2000-07-07 | 2003-06-10 | A. V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| DK1331927T3 (da) | 2000-10-27 | 2008-05-05 | Leo Pharma As | Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid |
| RU2276177C2 (ru) | 2001-05-01 | 2006-05-10 | Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук | Получение гидрофильных, чувствительных к давлению адгезивов с оптимизированными адгезионными свойствами |
| EP1397132A4 (en) | 2001-05-25 | 2006-12-13 | Valley Forge Pharmaceuticals I | OPHTHALMIC PIRENZEPINE GEL |
| US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| US7415169B2 (en) | 2001-11-30 | 2008-08-19 | Koninklijke Philips Electronics N.V. | Medical viewing system and method for enhancing structures in noisy images |
| GB0202312D0 (en) | 2002-01-31 | 2002-03-20 | Disperse Technologies Plc | Polyaphron fuel compositions |
| GB0214793D0 (en) | 2002-06-26 | 2002-08-07 | Disperse Technologies Plc | Biliquid foam entrapment |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7053124B2 (en) | 2002-11-06 | 2006-05-30 | Disperse Limited | Aerosol delivery systems |
| US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| WO2005001643A2 (en) | 2003-06-21 | 2005-01-06 | J Maev Jack Ivan | Method and apparatus for encouraged visitation web advertising |
| FR2856301B1 (fr) | 2003-06-23 | 2007-08-03 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| WO2005004989A2 (en) | 2003-07-01 | 2005-01-20 | Todd Maibach | Film comprising therapeutic agents |
| GB0317868D0 (en) | 2003-07-30 | 2003-09-03 | Disperse Ltd | Biliquid foams with a high alcohol content and products formulated therefrom |
| GB0317869D0 (en) | 2003-07-30 | 2003-09-03 | Disperse Ltd | Improved drug delivery system |
| JP2007502823A (ja) | 2003-08-15 | 2007-02-15 | キューエルティー・ユーエスエイ・インコーポレーテッド | 接着性および生体侵食性の経粘膜薬物送達システム |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| JP2005123083A (ja) | 2003-10-17 | 2005-05-12 | Dainippon Screen Mfg Co Ltd | 塗布組成物および有機ｅｌ素子の製造方法 |
| EP1952808A3 (en) | 2003-11-21 | 2008-09-03 | Galderma Research & Development | Composition in the form of a spray comprising calcitriol |
| FR2862540B1 (fr) | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| GB0404403D0 (en) | 2004-02-27 | 2004-03-31 | Disperse Ltd | Dispersions |
| FR2871696B1 (fr) | 2004-06-17 | 2006-11-10 | Galderma Sa | Composition topique pour le traitement du psoriasis |
| CA2567683A1 (en) | 2004-06-17 | 2005-12-29 | Galderma S.A. | Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase |
| KR20070027587A (ko) | 2004-06-17 | 2007-03-09 | 갈데르마 소시에떼아노님 | 실리콘제, 코르티코스테로이드 및 비타민 ｄ 또는 이의유도체를 함유하는 건선 치료용 조성물 |
| FR2871693B1 (fr) | 2004-06-17 | 2006-08-25 | Galderma Sa | Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis |
| FR2871700B1 (fr) | 2004-06-17 | 2006-11-17 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse |
| FR2871699A1 (fr) | 2004-06-17 | 2005-12-23 | Galderma Sa | Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie |
| FR2871695B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises |
| FR2871694B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises |
| FR2871697B1 (fr) | 2004-06-17 | 2007-06-29 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile |
| JP2008502646A (ja) | 2004-06-17 | 2008-01-31 | ガルデルマ・ソシエテ・アノニム | プロピオン酸クロベタゾールとカルシトリオールとの組合せ、アルコール相、および油性相を含むスプレーの形態の組成物 |
| FR2871698B1 (fr) | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse |
| IT1333365B1 (it) | 2004-09-09 | 2006-04-11 | Alberto Fiorenzi | Apparecchiatura e procedimento per realizzare una vela e relativa vela realizzata |
| AU2005304034B2 (en) | 2004-11-09 | 2012-02-16 | Santen Sas | Ophthalmic emulsions containing an immunosuppressive agent |
| WO2006111426A1 (en) | 2005-04-19 | 2006-10-26 | Galderma S.A. | Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology |
| CA2611147C (en) | 2005-06-01 | 2013-04-09 | Stiefel Research Australia Pty Ltd. | Topical emulsion formulation |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| US20070219127A1 (en) * | 2006-03-20 | 2007-09-20 | Walt John G | Cyclosporin a compositions |
| US8110526B2 (en) | 2006-04-14 | 2012-02-07 | The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Arsenic absorbing composition and methods of use |
| US8188052B2 (en) * | 2006-05-19 | 2012-05-29 | Scynexis, Inc. | Method for the treatment and prevention of ocular disorders |
| EP1970049A1 (en) | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with vitamin D and corticosteroid |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| EP1970048A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with vitamin D |
| EP1970047A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with a corticosteroid |
| EP2008651A1 (en) * | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
| GB0712389D0 (en) | 2007-06-26 | 2007-08-01 | Drug Delivery Solutions Ltd | A Pharmaceutical composition |
| WO2009007409A2 (en) | 2007-07-09 | 2009-01-15 | Novagali Pharma Sa | Oil in water emulsion comprising nsaids and quaternary ammonium halides |
| KR101805116B1 (ko) | 2007-12-04 | 2017-12-06 | 산텐 에스에이에스 | 덱사메타손 팔미테이트와 같은 코르티코스테로이드 전구약물을 포함하는 안과질환 치료용 조성물 |
| US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
| US20100272875A1 (en) | 2009-04-24 | 2010-10-28 | Monsanto Technology Llc | Omega-3 enriched cereal, granola, and snack bars |
| WO2010127301A1 (en) * | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Method of treating allergic conjunctivitis with cyclosporin compositions |
| US9480645B2 (en) | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| PT2686017T (pt) | 2011-03-14 | 2019-10-24 | Drug Delivery Solutions Ltd | Uma composição oftálmica. |
-
2012
- 2012-03-14 PT PT127083582T patent/PT2686017T/pt unknown
- 2012-03-14 WO PCT/EP2012/054498 patent/WO2012123515A1/en active Application Filing
- 2012-03-14 CN CN201810366640.2A patent/CN108273065B/zh active Active
- 2012-03-14 JP JP2013558425A patent/JP6105494B2/ja active Active
- 2012-03-14 DK DK12708358.2T patent/DK2686017T3/da active
- 2012-03-14 RU RU2013145709A patent/RU2639472C2/ru active
- 2012-03-14 ES ES12708358T patent/ES2736256T3/es active Active
- 2012-03-14 CN CN201280013225.XA patent/CN103533962B/zh active Active
- 2012-03-14 BR BR112013023458A patent/BR112013023458B1/pt active IP Right Grant
- 2012-03-14 AU AU2012228273A patent/AU2012228273B2/en active Active
- 2012-03-14 PL PL12708358T patent/PL2686017T3/pl unknown
- 2012-03-14 US US14/003,871 patent/US9610245B2/en active Active
- 2012-03-14 EP EP12708358.2A patent/EP2686017B1/en active Active
- 2012-03-14 CA CA2829164A patent/CA2829164C/en active Active
- 2012-03-14 HU HUE12708358A patent/HUE045467T2/hu unknown
- 2012-03-14 SI SI201231672T patent/SI2686017T1/sl unknown
-
2017
- 2017-03-09 US US15/454,806 patent/US10154959B1/en active Active
-
2019
- 2019-09-20 HR HRP20191711 patent/HRP20191711T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013023458B1 (pt) | 2020-04-07 |
| EP2686017A1 (en) | 2014-01-22 |
| WO2012123515A1 (en) | 2012-09-20 |
| AU2012228273B2 (en) | 2015-08-20 |
| CN108273065B (zh) | 2020-07-31 |
| US10154959B1 (en) | 2018-12-18 |
| CN108273065A (zh) | 2018-07-13 |
| AU2012228273A1 (en) | 2013-05-02 |
| DK2686017T3 (da) | 2019-10-07 |
| BR112013023458A2 (pt) | 2016-12-06 |
| JP2014509602A (ja) | 2014-04-21 |
| US20130345150A1 (en) | 2013-12-26 |
| CN103533962B (zh) | 2018-05-18 |
| HUE045467T2 (hu) | 2020-01-28 |
| RU2639472C2 (ru) | 2017-12-21 |
| PL2686017T3 (pl) | 2020-03-31 |
| EP2686017B1 (en) | 2019-07-03 |
| US9610245B2 (en) | 2017-04-04 |
| PT2686017T (pt) | 2019-10-24 |
| CA2829164C (en) | 2020-03-31 |
| ES2736256T3 (es) | 2019-12-27 |
| RU2013145709A (ru) | 2015-04-20 |
| JP6105494B2 (ja) | 2017-03-29 |
| CN103533962A (zh) | 2014-01-22 |
| SI2686017T1 (sl) | 2019-11-29 |
| CA2829164A1 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191711T1 (hr) | Oftalmološki pripravak | |
| Chime et al. | Nanoemulsions—advances in formulation, characterization and applications in drug delivery | |
| ES2617683T3 (es) | Composiciones oftálmicas basadas en ácidos grasos Omega-3 y Omega-6 poliinsaturados | |
| ES2745084T3 (es) | Composiciones de alcanos semifluorados para uso en el tratamiento de la queraconjuntivitis seca | |
| JP7250689B2 (ja) | 活性化合物のための局所送達系 | |
| JP6023181B2 (ja) | 爪に投与するための医薬組成物 | |
| TWI434705B (zh) | 局部用組成物 | |
| Morsi et al. | Nanoemulsion as a novel ophthalmic delivery system for acetazolamide | |
| BR112015004997B1 (pt) | Composições oftálmicas contendo misturas de alcanos semifluorados | |
| JP2008505177A (ja) | 目の障害および状態を治療するための組成物および方法 | |
| WO2012059158A1 (de) | Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator | |
| WO2015085899A1 (en) | Stabilized all-aqueous emulsions and methods of making and using thereof | |
| WO2020220141A1 (en) | Cannabinoid stock transdermal formulations | |
| RU2017127485A (ru) | Композиция, способ трансдермальной доставки полиафрона, способ контролируемого высвобождения ингредиента | |
| RU2414887C2 (ru) | Стерильный многофазный капельный глазной препарат | |
| Katiyar et al. | Microemulsions: A novel drug carrier system | |
| JP7240175B2 (ja) | 貯蔵安定性の眼用組成物 | |
| KR20140043562A (ko) | 무복계면 라타노프로스트 및 그 제조방법 | |
| ES2731151T3 (es) | Composiciones oftálmicas basadas en ácidos poliinsaturados y triacilgliceroles | |
| CN105228631A (zh) | 包含透明质酸、毛蕊花糖苷和甘油磷酸肌醇的局部制剂 | |
| VISHWAKARMA et al. | Emulgel emergent systems: at a glance for topical drug delivery | |
| KR20240031362A (ko) | 수성 겔 조성물 | |
| RU2777644C2 (ru) | Системы доставки для местного нанесения для активных веществ | |
| Lima et al. | Technological development of microemulsions with perspectives for pain treatment: a patent | |
| JP2023542435A (ja) | 硝子体内投与のための水中油型油エマルション |